
Davide Lazzarotto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1229911/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Role of Wilms' Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia. Journal of Clinical Medicine, 2022, 11, 3306.	2.4	10
2	Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma. Expert Opinion on Drug Safety, 2021, 20, 751-756.	2.4	1
3	Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interventional study. Journal of Antimicrobial Chemotherapy, 2020, 75, 3029-3037.	3.0	24
4	Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory Tâ€cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study. American Journal of Hematology, 2020, 95, 1466-1472.	4.1	42
5	Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and P. aeruginosa. Pharmaceutics, 2020, 12, 785.	4.5	6
6	18F-FDG Positron Emission Tomography (PET) Scan as a Useful Tool to Assess Response to Antimycotic Therapy in Disseminated Invasive Mycosis in Acute Myeloid Leukemia. Mycopathologia, 2020, 185, 597-598.	3.1	0
7	Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. Journal of Antimicrobial Chemotherapy, 2017, 72, 2342-2350.	3.0	26